Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients
1. Purpose
Ensure Americans have access to the most-favored-nation price for pharmaceuticals, preventing subsidies of low-cost prescription drugs in other countries.
2. Key Actions And Directives
- Establish Fair International Pricing: The Secretary of Commerce and the U.S. Trade Representative will ensure foreign countries do not force inflated prices on American consumers.
- Facilitate Direct-to-Consumer Sales: The Secretary of Health and Human Services will support pharmaceutical manufacturers selling at most-favored-nation prices to American patients.
- Rulemaking if Progress Lacking: If significant progress on pricing is not achieved, propose rules to implement most-favored-nation pricing and assess the safety of drug importation.
3. Important Points
- Addressing Pharmaceutical Imbalance: The Executive Order challenges the disparity whereby U.S. drug prices exceed those of other nations, requiring Americans to subsidize global health systems.
- Combatting Global Freeloading: It seeks to put an end to practices where foreign markets exploit lower U.S. drug costs, aiming for fairer pharmaceutical pricing worldwide.
- No Enforceable Rights Created: The order emphasizes it does not create new rights or alter existing authorities under U.S. law.
- Public Accessibility via Federal Register: The publication mandates transparency, allowing the public to access the provisions and implications of the Executive Order.
- Signed Date: Executive Order 14297 was signed on May 12, 2025, marking a proactive stance on drug pricing policy.
Disclaimer: ExecBrief's are AI generated, Please verify with the original source to confirm
Click here to provide feedback to help us improve your experience!
Comments